Inactivated influenza virus vaccine for nasal or oral application

Abstract

The invention relates to nasal or oral administration of a compound containing inactivated influenza virus antigen and aluminum as adjuvant for the prophylaxis of influenza virus infections. Said vaccine is especially suitable for inducing a mucosal IgA immune response and systemic IgG immune response.

1 . Use of a composition containing inactivated influenza virus and aluminum as an adjuvant for the production of a influenza virus vaccine for nasal or oral administration.  
   
   
       2 - 8 . (canceled)  
   
   
       9 . A storage stable influenza virus vaccine composition for oral administration, wherein the composition comprises 
 inactivated influenza virus antigen and an aluminum salt and is free of media proteins, wherein the antigen is treated by one or more steps selected from the group consisting of centrifugation, DNAse treatment, diafiltration and sterile filtration.    
   
   
       10 . The storage stable influenza vaccine composition of  claim 9 , wherein the aluminum salt is aluminum hydroxide or aluminum phosphate.  
   
   
       11 . The storage stable influenza vaccine composition of  claim 9 , wherein the antigen is present at 1.5 μg to 50 μg per vaccine dose.  
   
   
       12 . The storage stable influenza vaccine composition of  claim 9 , wherein the aluminum salt is present in a concentration of 0.05% to 0.5%.  
   
   
       13 . The storage stable influenza vaccine composition of  claim 9 , wherein the antigen is present at 1.5 μg to 50 μg per vaccine dose and the aluminum salt is present in a concentration of 0.05% to 0.5%.  
   
   
       14 . The storage stable influenza vaccine composition of  claim 9 , wherein the composition is in the form of a drop, a spray or inhalation form.  
   
   
       15 . The storage stable influenza vaccine composition of  claim 9 , wherein the composition is in the form of a tablet, gelatin capsule or microcapsule.  
   
   
       16 . The storage stable influenza vaccine composition of  claim 9 , wherein the composition is in the form of a cream or emulsion.  
   
   
       17 . A storage stable influenza virus vaccine composition for nasal administration, wherein the composition comprises 
 inactivated influenza virus antigen and an aluminum salt and is free of media proteins, wherein the antigen is treated by one or more steps selected from the group consisting of centrifugation, DNAse treatment, diafiltration and sterile filtration.    
   
   
       18 . The storage stable influenza vaccine composition of  claim 17 , wherein the aluminum salt is aluminum hydroxide or aluminum phosphate.  
   
   
       19 . The storage stable influenza vaccine composition of  claim 17 , wherein the antigen is present at 1.5 μg to 50 μg per vaccine dose.  
   
   
       20 . The storage stable influenza vaccine composition of  claim 17 , wherein the aluminum salt is present in a concentration of 0.05% to 0.5%.  
   
   
       21 . The storage stable influenza vaccine composition of  claim 17 , wherein the antigen is present at 1.5 μg to 50 μg per vaccine dose and the aluminum salt is present in a concentration of 0.05% to 0.5%.  
   
   
       22 . The storage stable influenza vaccine composition of  claim 17 , wherein the composition is in the form of a drop, a spray or inhalation form.  
   
   
       23 . The storage stable influenza vaccine composition of  claim 17 , wherein the composition is in the form of a cream or emulsion.